What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

BACKGROUND: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vale, C L, Fisher, D J, White, I R, Carpenter, J R, Burdett, S, Clarke, N W, Fizazi, K, Gravis, G, James, N D, Mason, M D, Parmar, M K B, Rydzewska, L H, Sweeney, C J, Spears, M R, Sydes, M R, Tierney, J F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961275/
https://www.ncbi.nlm.nih.gov/pubmed/29788164
http://dx.doi.org/10.1093/annonc/mdy071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961275/
https://www.ncbi.nlm.nih.gov/pubmed/29788164
http://dx.doi.org/10.1093/annonc/mdy071

Ejemplares similares